EGFR and non-small cell lung carcinoma: Clinical trials combining dasatinib with first- and second-generation EGFR-TKIs have reported no objective response in patients with EGFR-mutant NSCLC resistant to prior EGFR-TKI therapy (22, 23) and a low response rate in unselected advanced NSCLC (24).